Our funding events in Follow-on funding are shown below.
Follow-on funding is designed to help demonstrate the commercial potential of ideas arising from Research Council funded research. It provides financial support at the very early or pre-seed stage of turning research outputs into a commercial proposition. The programme enables activities essential to preparing a robust business plan and secure further funding to progress commercially. This might include:
• Undertaking further scientific and technical development of an idea.
• Improving an IP position through, for example, supporting further work to exemplify or broaden patent claims.
• Gaining further information about the market for the new products or process.
• Identifying potential licensees or opportunities for joint ventures.
Eligibility: Applicants must be researchers employed by a UK university or BBSRC funded institute and must hold a permanent academic post and have or have had grant funding, with relevance to the application, from the BBSRC. Projects must draw substantially on previous BBSRC-funded research.
Funding: Typical grants are expected to be under £250,000 (fEC) and 12 months in duration, of which BBSRC will pay the standard 80% fEC proportion. A small number of larger strategic awards (Super Follow-on Funding) are also available which will be valued between £250,000 and £1M per annum (fEC) and will be 12-24 months in duration, of which BBSRC will pay the standard 80% fEC proportion.
Applications for this call require a letter of support from Cambridge Enterprise and their involvement in the management of any successful grants. Potential applicants should contact Iain.Thomas@enterprise.cam.ac.uk as soon as possible to discuss their project.
For more information see: http://www.bbsrc.ac.uk/business/commercialisation/follow-on.aspx
The BBSRC new pathfinder scheme enables potential follow-on funding applicants to secure small amounts of funding to carry out preliminary commercial activities.
Therapeutics, Devices and Diagnostics Development
The Developmental Pathway Funding Scheme/Developmental Clinical Studies scheme (DPFS/DCS) supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies.
The DPFS/DCS scheme combines the previous individual translational funding schemes, permitting a more flexible and integrated approach to the development of new interventions and diagnostics. This scheme forms part of the MRC’s Translational Research Strategy.
Supporting either early- or late-stage product development, i4i is positioned to transform the translation of healthcare technologies for increased patient benefits